ABIOMED Stock Price, News & Analysis (NASDAQ:ABMD)

$225.89 1.76 (0.79 %)
(As of 01/18/2018 04:00 PM ET)
Previous Close$225.89
Today's Range$224.00 - $228.08
52-Week Range$103.53 - $228.08
Volume332,510 shs
Average Volume271,724 shs
Market Capitalization$9.99 billion
P/E Ratio111.28
Dividend YieldN/A
Beta0.15

About ABIOMED (NASDAQ:ABMD)

ABIOMED logoABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNASDAQ:ABMD
CUSIP00365410
Phone+1-978-7775410

Debt

Debt-to-Equity Ratio0.02%
Current Ratio5.84%
Quick Ratio5.20%

Price-To-Earnings

Trailing P/E Ratio111.275862068966
Forward P/E Ratio93.73
P/E Growth2.88

Sales & Book Value

Annual Sales$445.30 million
Price / Sales22.43
Cash Flow$1.39 per share
Price / Cash162.83
Book Value$10.38 per share
Price / Book21.76

Profitability

Trailing EPS$2.03
Net Income$52.11 million
Net Margins18.27%
Return on Equity13.89%
Return on Assets11.83%

Miscellaneous

Employees908
Outstanding Shares44,220,000

ABIOMED (NASDAQ:ABMD) Frequently Asked Questions

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) released its quarterly earnings results on Thursday, October, 26th. The medical equipment provider reported $0.54 EPS for the quarter, topping the consensus estimate of $0.38 by $0.16. The medical equipment provider earned $132.80 million during the quarter, compared to analyst estimates of $131.18 million. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The company's quarterly revenue was up 28.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.20 earnings per share. View ABIOMED's Earnings History.

When will ABIOMED make its next earnings announcement?

ABIOMED is scheduled to release their next quarterly earnings announcement on Thursday, February, 1st 2018. View Earnings Estimates for ABIOMED.

Where is ABIOMED's stock going? Where will ABIOMED's stock price be in 2018?

7 equities research analysts have issued 12 month price objectives for ABIOMED's shares. Their predictions range from $140.00 to $250.00. On average, they expect ABIOMED's stock price to reach $197.00 in the next year. View Analyst Ratings for ABIOMED.

Who are some of ABIOMED's key competitors?

Who are ABIOMED's key executives?

ABIOMED's management team includes the folowing people:

  • Michael R. Minogue, Chairman of the Board, President, Chief Executive Officer (Age 50)
  • Ian McLeod, Principal Financial Officer, Principal Accounting Officer, Vice President, Controller
  • David M. Weber, Chief Operating Officer (Age 55)
  • William J. Bolt, Senior Vice President, Global Quality, Regulatory and Clinical Operations (Age 65)
  • Andrew J. Greenfield, Vice President, General Manager - Global Marketing (Age 44)
  • Michael G. Howley, Vice President, General Manager - Global Sales and Marketing (Age 53)
  • Dorothy E. Puhy, Lead Independent Director (Age 65)
  • Jeannine M. Rivet, Independent Director (Age 69)
  • Eric A. Rose M.D., Independent Director (Age 66)
  • Martin P. Sutter, Independent Director (Age 62)

Who owns ABIOMED stock?

ABIOMED's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.31%), Country Trust Bank (0.25%), Frontier Capital Management Co. LLC (0.11%), Hamilton Lane Advisors LLC (0.05%), Louisiana State Employees Retirement System (0.02%) and Creative Planning (0.01%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Who sold ABIOMED stock? Who is selling ABIOMED stock?

ABIOMED's stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC and Louisiana State Employees Retirement System. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Michael G Howley and Paul Thomas. View Insider Buying and Selling for ABIOMED.

Who bought ABIOMED stock? Who is buying ABIOMED stock?

ABIOMED's stock was bought by a variety of institutional investors in the last quarter, including Country Trust Bank, Schwab Charles Investment Management Inc., Hamilton Lane Advisors LLC, Bank of Montreal Can, Creative Planning, Fox Run Management L.L.C. and Crow Point Partners LLC. View Insider Buying and Selling for ABIOMED.

How do I buy ABIOMED stock?

Shares of ABIOMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABIOMED stock can currently be purchased for approximately $225.89.

How big of a company is ABIOMED?

ABIOMED has a market capitalization of $9.99 billion and generates $445.30 million in revenue each year. The medical equipment provider earns $52.11 million in net income (profit) each year or $2.03 on an earnings per share basis. ABIOMED employs 908 workers across the globe.

How can I contact ABIOMED?

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS, MA 01923-2575, United States. The medical equipment provider can be reached via phone at +1-978-7775410 or via email at [email protected]


MarketBeat Community Rating for ABIOMED (ABMD)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  297 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  518
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ABIOMED (NASDAQ:ABMD) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.712.752.86
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $197.00$185.50$174.71$150.00
Price Target Upside: 6.26% downside3.85% downside0.50% upside6.27% upside

ABIOMED (NASDAQ:ABMD) Consensus Price Target History

Price Target History for ABIOMED (NASDAQ:ABMD)

ABIOMED (NASDAQ:ABMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2018Jefferies GroupBoost Price TargetBuy$250.00MediumView Rating Details
1/4/2018Piper Jaffray CompaniesReiterated RatingBuyHighView Rating Details
11/1/2017SunTrust BanksReiterated RatingBuy$195.00N/AView Rating Details
10/29/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
10/12/2017Leerink SwannReiterated RatingOutperform$180.00 -> $200.00N/AView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual Weight$135.00 -> $140.00LowView Rating Details
6/8/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$150.00N/AView Rating Details
4/10/2016BenchmarkReiterated RatingBuy$145.00N/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

ABIOMED (NASDAQ:ABMD) Earnings History and Estimates Chart

Earnings by Quarter for ABIOMED (NASDAQ:ABMD)

ABIOMED (NASDAQ ABMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2018$0.50N/AView Earnings Details
10/26/2017Q2 2018$0.38$0.54$131.18 million$132.80 millionViewN/AView Earnings Details
7/27/2017Q1 2018$0.42$0.45$130.83 million$132.47 millionViewN/AView Earnings Details
5/4/2017Q4 2017$0.33$0.33$122.82 million$124.68 millionViewListenView Earnings Details
1/26/2017Q317$0.29$0.34$112.71 million$114.70 millionViewListenView Earnings Details
10/27/2016Q217$0.24$0.20$103.16 million$103.00 millionViewListenView Earnings Details
7/28/2016Q117$0.23$0.29$97.23 million$103.00 millionViewListenView Earnings Details
5/3/2016Q416$0.19$0.24$90.52 million$94.00 millionViewN/AView Earnings Details
2/4/2016Q316$0.15$0.23$80.04 million$85.80 millionViewListenView Earnings Details
10/29/2015Q2$0.13$0.17$74.56 million$76.30 millionViewListenView Earnings Details
8/4/2015Q116$0.08$0.20$66.27 million$73.40 millionViewN/AView Earnings Details
5/5/2015Q415$0.12$0.28$62.55 million$67.60 millionViewN/AView Earnings Details
1/27/2015Q315$0.03$0.30$53.20 million$62.00 millionViewN/AView Earnings Details
10/30/2014Q215$0.02$0.09$48.80 million$51.80 millionViewN/AView Earnings Details
7/31/2014Q115$0.02($0.04)$297.10 million$48.80 millionViewN/AView Earnings Details
5/1/2014Q414$0.09$0.09$50.93 million$50.40 millionViewN/AView Earnings Details
1/31/2014Q314$0.05$0.11$46.00 million$46.20 millionViewN/AView Earnings Details
11/6/2013Q214$0.03$0.03$43.75 million$44.30 millionViewN/AView Earnings Details
8/1/2013Q1 2014$0.06($0.04)$42.93 million$42.70 millionViewN/AView Earnings Details
5/2/2013Q4 2013$0.08$0.09$41.87 million$43.70 millionViewN/AView Earnings Details
2/6/2013Q3 2013$0.07$0.07$38.04 million$38.30 millionViewN/AView Earnings Details
11/1/2012Q213$0.05$0.20$37.47 million$37.40 millionViewN/AView Earnings Details
8/2/2012$0.10$0.16ViewN/AView Earnings Details
5/16/2012$0.07$0.07ViewN/AView Earnings Details
2/3/2012($0.01)$0.07ViewN/AView Earnings Details
11/3/2011($0.09)$0.02ViewN/AView Earnings Details
8/4/2011($0.06)($0.03)ViewN/AView Earnings Details
5/18/2011($0.04)($0.05)ViewN/AView Earnings Details
2/3/2011($0.09)($0.02)ViewN/AView Earnings Details
11/4/2010Q2 2011($0.14)($0.09)ViewN/AView Earnings Details
8/4/2010Q1 2011($0.14)($0.14)ViewN/AView Earnings Details
5/19/2010Q4 2010($0.12)($0.11)ViewN/AView Earnings Details
2/4/2010Q3 2010($0.18)($0.11)ViewN/AView Earnings Details
11/5/2009Q2 2010($0.21)($0.21)ViewN/AView Earnings Details
8/6/2009Q1 2010($0.20)($0.20)ViewN/AView Earnings Details
5/12/2009Q4 2009($0.17)($0.22)ViewN/AView Earnings Details
2/5/2009Q3 2009($0.17)($0.20)ViewN/AView Earnings Details
11/10/2008Q2 2009($0.21)($0.18)ViewN/AView Earnings Details
8/7/2008Q1 2009($0.21)($0.28)ViewN/AView Earnings Details
5/21/2008Q4 2008($0.19)($0.25)ViewN/AView Earnings Details
2/7/2008Q3 2008($0.20)($0.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

ABIOMED (NASDAQ:ABMD) Earnings Estimates

2018 EPS Consensus Estimate: $1.82
2019 EPS Consensus Estimate: $2.47
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.40$0.43$0.41
Q2 20183$0.32$0.38$0.35
Q3 20183$0.46$0.58$0.50
Q4 20183$0.51$0.66$0.56
Q1 20192$0.58$0.63$0.61
Q2 20191$0.51$0.51$0.51
Q3 20191$0.62$0.62$0.62
Q4 20192$0.65$0.82$0.74
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for ABIOMED (NASDAQ:ABMD)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ABIOMED (NASDAQ ABMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 90.75%
Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)
Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

ABIOMED (NASDAQ ABMD) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/30/2017Dorothy E PuhyDirectorSell6,364$179.08$1,139,665.1239,532View SEC Filing  
10/30/2017Michael G HowleyVPSell10,000$178.64$1,786,400.0056,757View SEC Filing  
10/2/2017Andrew J GreenfieldVPSell11,282$169.32$1,910,268.24View SEC Filing  
8/30/2017Eric A Md RoseDirectorSell982$145.17$142,556.9413,634View SEC Filing  
8/24/2017Eric A Md RoseDirectorSell23,018$151.09$3,477,789.6224,652View SEC Filing  
8/15/2017Paul ThomasDirectorSell10,000$154.71$1,547,100.0012,172View SEC Filing  
7/31/2017David M WeberCOOSell16,500$147.63$2,435,895.00125,122View SEC Filing  
5/16/2017Michael G HowleyVPSell18,279$133.56$2,441,343.2462,105View SEC Filing  
5/8/2017David M WeberCOOSell21,250$130.89$2,781,412.50123,771View SEC Filing  
5/8/2017Dorothy E PuhyDirectorSell13,500$131.12$1,770,120.0038,249View SEC Filing  
5/8/2017Michael G HowleyVPSell600$132.84$79,704.0048,305View SEC Filing  
3/17/2017Andrew J GreenfieldVPSell10,000$124.00$1,240,000.0066,307View SEC Filing  
12/13/2016Dorothy E PuhyDirectorSell8,000$120.00$960,000.0032,749View SEC Filing  
11/30/2016Eric A Md RoseDirectorSell8,000$110.81$886,480.0021,259View SEC Filing  
9/22/2016Michael R MinogueCEOSell28,039$127.07$3,562,915.73215,488View SEC Filing  
9/21/2016Michael R MinogueCEOSell5,034$127.07$639,670.38215,782View SEC Filing  
9/19/2016Michael R MinogueCEOSell58,710$127.00$7,456,170.00215,782View SEC Filing  
8/15/2016Dorothy E PuhyDirectorSell5,160$123.94$639,530.4024,749View SEC Filing  
8/10/2016Dorothy E PuhyDirectorSell3,900$122.31$477,009.0033,811View SEC Filing  
8/8/2016Michael G HowleyVPSell17,853$119.20$2,128,077.6065,558View SEC Filing  
8/1/2016Henri A TermeerDirectorSell25,866$118.70$3,070,294.20325,778View SEC Filing  
6/29/2016Michael G HowleyVPSell10,000$106.58$1,065,800.0065,558View SEC Filing  
6/7/2016Andrew J GreenfieldVPSell9,000$104.16$937,440.0065,234View SEC Filing  
5/23/2016David M WeberCOOSell4,342$96.97$421,043.74100,159View SEC Filing  
5/16/2016David M WeberCOOSell5,604$94.56$529,914.24116,783View SEC Filing  
5/6/2016David M WeberCOOSell2,145$93.82$201,243.90117,411View SEC Filing  
5/5/2016David M WeberCOOSell52,000$95.27$4,954,040.00121,676View SEC Filing  
5/5/2016Paul ThomasDirectorSell7,500$95.14$713,550.0028,811View SEC Filing  
4/18/2016Andrew J GreenfieldVPSell10,000$99.10$991,000.0061,186View SEC Filing  
4/13/2016Michael G HowleyVPSell9,800$98.64$966,672.0062,268View SEC Filing  
4/8/2016Michael G HowleyVPSell200$98.80$19,760.0052,668View SEC Filing  
4/1/2016Dorothy E PuhyDirectorSell10,000$95.02$950,200.0047,792View SEC Filing  
3/31/2016Andrew J GreenfieldVPSell15,000$94.11$1,411,650.0058,941View SEC Filing  
3/24/2016David M WeberCOOSell5,235$89.93$470,783.55113,411View SEC Filing  
3/22/2016Andrew J GreenfieldVPSell24,800$89.06$2,208,688.0073,614View SEC Filing  
3/22/2016Dorothy E PuhyDirectorSell10,000$90.30$903,000.0052,190View SEC Filing  
3/21/2016Andrew J GreenfieldVPSell19,572$89.07$1,743,278.0473,614View SEC Filing  
3/10/2016Andrew J GreenfieldVPSell200$89.00$17,800.0054,242View SEC Filing  
3/8/2016David M WeberCOOSell17,521$85.20$1,492,789.20125,761View SEC Filing  
3/8/2016William J BoltSVPSell17,510$85.19$1,491,676.9098,392View SEC Filing  
3/7/2016David M WeberCOOSell8,111$85.21$691,138.31125,761View SEC Filing  
3/7/2016Dorothy E PuhyDirectorSell4,000$85.00$340,000.0066,190View SEC Filing  
3/7/2016William J BoltSVPSell7,987$85.20$680,492.4098,392View SEC Filing  
2/8/2016Dorothy E. PuhyDirectorSell4,000$80.47$321,880.0062,190View SEC Filing  
8/19/2015Michael R. MinogueCEOSell146,800$104.87$15,394,916.00239,718View SEC Filing  
8/17/2015Dorothy E PuhyDirectorSell2,580$103.91$268,087.80View SEC Filing  
8/14/2015Dorothy E PuhyDirectorSell2,580$105.27$271,596.60View SEC Filing  
7/17/2015Michael G HowleyVPSell21,295$70.00$1,490,650.00View SEC Filing  
6/15/2015Andrew J GreenfieldVPSell3,185$65.00$207,025.00View SEC Filing  
5/29/2015Martin P SutterDirectorBuy7,500$60.17$451,275.00View SEC Filing  
5/27/2015David M WeberCOOSell17,968$60.77$1,091,915.36View SEC Filing  
5/12/2015Michael G HowleyVPSell17,353$66.47$1,153,453.91View SEC Filing  
5/7/2015Andrew J GreenfieldVPSell3,500$71.00$248,500.00View SEC Filing  
5/7/2015Robert BowenCFOSell2,372$71.52$169,645.44View SEC Filing  
5/6/2015David M WeberCOOSell1,605$73.72$118,320.60View SEC Filing  
5/6/2015Michael R MinogueCEOSell8,840$73.12$646,380.80View SEC Filing  
5/6/2015William J BoltSVPSell1,750$74.27$129,972.50View SEC Filing  
3/23/2015David M WeberCOOSell3,765$71.08$267,616.20View SEC Filing  
10/31/2014Andrew J GreenfieldVPSell15,000$31.90$478,500.00View SEC Filing  
10/31/2014Michael R MinogueCEOSell164,000$31.14$5,106,960.00View SEC Filing  
7/28/2014Michael R MinogueCEOSell82,383$26.30$2,166,672.90View SEC Filing  
5/27/2014Andrew J GreenfieldVPSell7,026$21.10$148,248.60View SEC Filing  
5/27/2014David M WeberCOOSell10,172$21.11$214,730.92View SEC Filing  
5/27/2014Michael R MinogueCEOSell90,001$21.19$1,907,121.19View SEC Filing  
5/27/2014Robert BowenCFOSell6,820$21.11$143,970.20View SEC Filing  
5/27/2014William J BoltSVPSell8,029$21.10$169,411.90View SEC Filing  
5/15/2014David WeberCOOSell1,425$20.94$29,839.50130,482View SEC Filing  
5/15/2014Michael HowleyVPSell1,267$20.94$26,530.9874,486View SEC Filing  
5/15/2014Michael MinogueCEOSell4,433$20.94$92,827.02260,912View SEC Filing  
5/15/2014William BoltSVPSell1,110$20.94$23,243.4094,205View SEC Filing  
1/10/2014Robert BowenCFOSell37,500$30.00$1,125,000.0066,929View SEC Filing  
9/3/2013David WeberCOOSell6,500$24.00$156,000.00126,907View SEC Filing  
9/3/2013William BoltSVPSell20,000$24.00$480,000.0089,718View SEC Filing  
8/14/2013William BoltSVPSell21,534$23.35$502,818.9089,718View SEC Filing  
8/13/2013David WeberCOOSell4,400$23.00$101,200.00133,407View SEC Filing  
8/13/2013Michael HowleyVPSell8,400$23.00$193,200.0068,753View SEC Filing  
8/5/2013David WeberCOOSell7,100$22.90$162,590.00137,807View SEC Filing  
8/5/2013Michael HowleyVPSell1,600$23.03$36,848.0077,153View SEC Filing  
8/5/2013Robert BowenCFOSell2,235$22.64$50,600.4066,929View SEC Filing  
8/5/2013W Gerald AustenDirectorSell8,000$22.85$182,800.00View SEC Filing  
8/5/2013William BoltSVPSell20,166$22.70$457,768.2098,552View SEC Filing  
7/31/2013Michael R MinogueCEOSell36,500$25.04$913,960.00View SEC Filing  
7/17/2013Michael G HowleyVPSell10,000$24.45$244,500.00View SEC Filing  
7/15/2013Robert BowenCFOSell40,786$23.50$958,471.00View SEC Filing  
7/11/2013Robert BowenCFOSell1,499$23.50$35,226.50View SEC Filing  
6/4/2013David M WeberCOOSell6,519$21.20$138,202.80View SEC Filing  
6/4/2013Michael G HowleyVPSell3,881$21.20$82,277.20View SEC Filing  
6/4/2013Michael R MinogueCEOSell17,667$21.23$375,070.41View SEC Filing  
6/4/2013Robert BowenCFOSell5,298$21.20$112,317.60View SEC Filing  
6/4/2013William J BoltSVPSell4,967$21.20$105,300.40View SEC Filing  
5/29/2013Michael R MinogueCEOSell58,833$21.83$1,284,324.39View SEC Filing  
5/28/2013David M WeberCOOSell6,018$22.18$133,479.24View SEC Filing  
5/28/2013Michael G HowleyVPSell5,476$22.18$121,457.68View SEC Filing  
5/28/2013Robert BowenCFOSell5,102$22.18$113,162.36View SEC Filing  
5/28/2013William J BoltSVPSell4,629$22.18$102,671.22View SEC Filing  
5/23/2013Andrew J GreenfieldVPSell1,666$21.63$36,035.58View SEC Filing  
5/23/2013Michael R MinogueCEOSell5,666$21.62$122,498.92View SEC Filing  
5/17/2013Robert BowenCFOSell2,715$23.50$63,802.50View SEC Filing  
5/9/2013Michael R MinogueCEOSell20,000$21.00$420,000.00View SEC Filing  
5/7/2013Henri A TermeerDirectorBuy100,000$19.86$1,986,000.00View SEC Filing  
2/25/2013Henri A TermeerDirectorBuy100,000$14.98$1,498,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ABIOMED (NASDAQ ABMD) News Headlines

Source:
DateHeadline
Breakout Watch: 99 A+ Funds Have Positions In This IBD 50 StockBreakout Watch: 99 A+ Funds Have Positions In This IBD 50 Stock
finance.yahoo.com - January 18 at 11:53 AM
Stocks Down, Energy Play Holds Firm; This Bitcoin ETF Finds 50-Day SupportStocks Down, Energy Play Holds Firm; This Bitcoin ETF Finds 50-Day Support
finance.yahoo.com - January 16 at 3:31 PM
ABIOMED, Inc. (ABMD) Given Consensus Recommendation of "Buy" by AnalystsABIOMED, Inc. (ABMD) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 15 at 7:42 AM
ABIOMED (ABMD) PT Raised to $250.00ABIOMED (ABMD) PT Raised to $250.00
www.americanbankingnews.com - January 14 at 7:28 AM
Abiomed At Top End Of Buy Zone With Earnings DueAbiomed At Top End Of Buy Zone With Earnings Due
finance.yahoo.com - January 10 at 11:37 AM
Phibro (PAHC) Strong on Animal Health Arm, Dull MFA Ails - NasdaqPhibro (PAHC) Strong on Animal Health Arm, Dull MFA Ails - Nasdaq
www.nasdaq.com - January 9 at 3:33 PM
Abiomed (ABMD) Prelim. Q3 Revenue Tops Views - StreetInsider.comAbiomed (ABMD) Prelim. Q3 Revenue Tops Views - StreetInsider.com
www.streetinsider.com - January 8 at 3:37 PM
Is ABIOMED Inc’s (NASDAQ:ABMD) Liquidity As Good As Its Solvency?Is ABIOMED Inc’s (NASDAQ:ABMD) Liquidity As Good As Its Solvency?
finance.yahoo.com - January 8 at 10:59 AM
Entellus (ENTL) Nears 52-Week High: What's Driving It?Entellus (ENTL) Nears 52-Week High: What's Driving It?
finance.yahoo.com - January 3 at 3:32 PM
5 Reasons Why You Should Buy Abiomed (ABMD) Stock Right Now5 Reasons Why You Should Buy Abiomed (ABMD) Stock Right Now
www.zacks.com - January 2 at 11:14 AM
$147.65 Million in Sales Expected for ABIOMED, Inc. (ABMD) This Quarter$147.65 Million in Sales Expected for ABIOMED, Inc. (ABMD) This Quarter
www.americanbankingnews.com - January 2 at 6:58 AM
Comparing ABIOMED (ABMD) and Mazor Robotics (MZOR)Comparing ABIOMED (ABMD) and Mazor Robotics (MZOR)
www.americanbankingnews.com - January 1 at 9:10 PM
Abiomed to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)Abiomed to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - December 29 at 3:32 PM
Abiomed to Present at the 36th Annual J.P. Morgan Healthcare ConferenceAbiomed to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 29 at 10:55 AM
ABIOMED (ABMD) Lifted to Buy at Zacks Investment ResearchABIOMED (ABMD) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - December 29 at 9:30 AM
ABIOMED (ABMD) Given New $220.00 Price Target at Jefferies GroupABIOMED (ABMD) Given New $220.00 Price Target at Jefferies Group
www.americanbankingnews.com - December 21 at 9:36 AM
ABIOMED, Inc. (ABMD) Given Average Rating of "Buy" by AnalystsABIOMED, Inc. (ABMD) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 21 at 8:12 AM
ETFs with exposure to ABIOMED, Inc. : December 18, 2017ETFs with exposure to ABIOMED, Inc. : December 18, 2017
finance.yahoo.com - December 18 at 3:31 PM
ABIOMED (ABMD) Downgraded by BidaskClub to "Hold"ABIOMED (ABMD) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - December 17 at 8:40 PM
Zacks: Analysts Expect ABIOMED, Inc. (ABMD) Will Post Quarterly Sales of $147.65 MillionZacks: Analysts Expect ABIOMED, Inc. (ABMD) Will Post Quarterly Sales of $147.65 Million
www.americanbankingnews.com - December 16 at 2:56 AM
$0.50 Earnings Per Share Expected for ABIOMED, Inc. (ABMD) This Quarter$0.50 Earnings Per Share Expected for ABIOMED, Inc. (ABMD) This Quarter
www.americanbankingnews.com - December 14 at 11:02 PM
ETFs with exposure to ABIOMED, Inc. : December 5, 2017ETFs with exposure to ABIOMED, Inc. : December 5, 2017
finance.yahoo.com - December 5 at 3:31 PM
Abiomed (ABMD) Up 10.5% Since Earnings Report: Can It Continue?Abiomed (ABMD) Up 10.5% Since Earnings Report: Can It Continue?
finance.yahoo.com - November 28 at 8:31 AM
 Brokerages Expect ABIOMED, Inc. (ABMD) Will Post Quarterly Sales of $147.65 Million Brokerages Expect ABIOMED, Inc. (ABMD) Will Post Quarterly Sales of $147.65 Million
www.americanbankingnews.com - November 28 at 3:48 AM
 Analysts Anticipate ABIOMED, Inc. (ABMD) to Announce $0.50 Earnings Per Share Analysts Anticipate ABIOMED, Inc. (ABMD) to Announce $0.50 Earnings Per Share
www.americanbankingnews.com - November 26 at 7:31 PM
ABIOMED, Inc. (ABMD) Receives Consensus Recommendation of "Buy" from AnalystsABIOMED, Inc. (ABMD) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 26 at 8:16 AM
ETFs with exposure to ABIOMED, Inc. : November 24, 2017ETFs with exposure to ABIOMED, Inc. : November 24, 2017
finance.yahoo.com - November 24 at 3:19 PM
ETFs with exposure to ABIOMED, Inc. : November 13, 2017ETFs with exposure to ABIOMED, Inc. : November 13, 2017
finance.yahoo.com - November 13 at 5:22 PM
Head to Head Review: ABIOMED (ABMD) & IRIDEX Corporation (IRIX)Head to Head Review: ABIOMED (ABMD) & IRIDEX Corporation (IRIX)
www.americanbankingnews.com - November 13 at 7:34 AM
ABIOMED, Inc. (ABMD) Expected to Announce Quarterly Sales of $147.65 MillionABIOMED, Inc. (ABMD) Expected to Announce Quarterly Sales of $147.65 Million
www.americanbankingnews.com - November 10 at 11:12 AM
Industry Group Rank Analytics Power Abiomed (ABMD) to Strong Buy - Investorplace.comIndustry Group Rank Analytics Power Abiomed (ABMD) to Strong Buy - Investorplace.com
investorplace.com - November 9 at 3:21 AM
ABIOMED, Inc. :ABMD-US: Earnings Analysis: Q2, 2018 By the Numbers : November 8, 2017ABIOMED, Inc. :ABMD-US: Earnings Analysis: Q2, 2018 By the Numbers : November 8, 2017
finance.yahoo.com - November 8 at 5:14 PM
ABIOMED, Inc. (ABMD) Expected to Post Earnings of $0.50 Per ShareABIOMED, Inc. (ABMD) Expected to Post Earnings of $0.50 Per Share
www.americanbankingnews.com - November 8 at 5:26 AM
ABIOMED, Inc. (ABMD) Upgraded at Zacks Investment ResearchABIOMED, Inc. (ABMD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - November 7 at 9:06 PM
Industry Group Rank Analytics Power Abiomed (ABMD) to Strong BuyIndustry Group Rank Analytics Power Abiomed (ABMD) to Strong Buy
investorplace.com - November 7 at 6:51 PM
De Burlo Group Inc Buys Applied Materials Inc, American Tower Corp, Netflix Inc, Sells C.R. ...De Burlo Group Inc Buys Applied Materials Inc, American Tower Corp, Netflix Inc, Sells C.R. ...
www.nasdaq.com - November 3 at 3:13 PM
ABIOMED, Inc. (ABMD) Stock Rating Reaffirmed by SunTrust Banks, Inc.ABIOMED, Inc. (ABMD) Stock Rating Reaffirmed by SunTrust Banks, Inc.
www.americanbankingnews.com - November 1 at 8:28 PM
ABIOMED, Inc. (ABMD) Director Sells $1,139,665.12 in StockABIOMED, Inc. (ABMD) Director Sells $1,139,665.12 in Stock
www.americanbankingnews.com - November 1 at 5:25 PM
Insider Selling: ABIOMED, Inc. (ABMD) VP Sells 10,000 Shares of StockInsider Selling: ABIOMED, Inc. (ABMD) VP Sells 10,000 Shares of Stock
www.americanbankingnews.com - November 1 at 5:24 PM
Abiomed (ABMD) Looks Good: Stock Adds 7.5% in Session - NasdaqAbiomed (ABMD) Looks Good: Stock Adds 7.5% in Session - Nasdaq
www.nasdaq.com - November 1 at 3:24 PM
Abiomed (ABMD) Looks Good: Stock Adds 7.5% in SessionAbiomed (ABMD) Looks Good: Stock Adds 7.5% in Session
finance.yahoo.com - November 1 at 3:24 PM
ETFs with exposure to ABIOMED, Inc. : November 1, 2017ETFs with exposure to ABIOMED, Inc. : November 1, 2017
finance.yahoo.com - November 1 at 3:24 PM
ABIOMED, Inc. (ABMD) Given Average Recommendation of "Buy" by BrokeragesABIOMED, Inc. (ABMD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 1 at 10:18 AM
Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2 - NasdaqAbiomed (ABMD) Earnings and Revenues Beat Estimates in Q2 - Nasdaq
www.nasdaq.com - October 30 at 3:25 PM
Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2
finance.yahoo.com - October 30 at 3:24 PM
FY2018 Earnings Estimate for ABIOMED, Inc. Issued By William Blair (ABMD)FY2018 Earnings Estimate for ABIOMED, Inc. Issued By William Blair (ABMD)
www.americanbankingnews.com - October 30 at 10:57 AM
Q3 2018 EPS Estimates for ABIOMED, Inc. Increased by Analyst (ABMD)Q3 2018 EPS Estimates for ABIOMED, Inc. Increased by Analyst (ABMD)
www.americanbankingnews.com - October 30 at 9:43 AM
Equities Analysts Offer Predictions for ABIOMED, Inc.s Q3 2018 Earnings (ABMD)Equities Analysts Offer Predictions for ABIOMED, Inc.'s Q3 2018 Earnings (ABMD)
www.americanbankingnews.com - October 30 at 9:42 AM
ABIOMEDs (ABMD) CEO Mike Minogue on Q2 2018 Results - Earnings Call TranscriptABIOMED's (ABMD) CEO Mike Minogue on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - October 28 at 3:54 PM
Abiomed Announces First Patient Treated with Impella® in Japan - GlobeNewswire (press release)Abiomed Announces First Patient Treated with Impella® in Japan - GlobeNewswire (press release)
globenewswire.com - October 27 at 10:40 PM

SEC Filings

ABIOMED (NASDAQ:ABMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ABIOMED (NASDAQ:ABMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ABIOMED (NASDAQ ABMD) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.